QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.005884v1 33/11/1700    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McGinnity, D. F. Articles by Riley, R. J. Search for Related Content PubMed PubMed Citation Articles by McGinnity, D. F. Articles by Riley, R. J.

PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES

Department of Physical & Metabolic Science, AstraZeneca R&D Charnwood, Bakewell Rd., Loughborough, Leicestershire, United Kingdom

The IC₅₀ values of 14 drugs were determined in recombinantly expressed CYP2C9 (rCYP2C9) and human hepatocytes and the data used to simulate clinical area under the plasma concentration-time curve (AUC) changes upon coadministration with prototypic CYP2C9 substrates. There was an excellent correlation between IC_{50, apparent} values determined using diclofenac and naproxen as CYP2C9 substrates (r² = 0.82, p < 0.0001), with values being generally higher in the naproxen assay. After correcting for nonspecific binding, the IC_{50, unbound} values were similar between the assays, for the majority of compounds. Two compounds, amiodarone and benzbromarone, demonstrated substrate-specific differences, activating naproxen O-demethylase to 250% of control activity at 1 mM and 1 µM, respectively, while inhibiting diclofenac 4'-hydroxylation with IC_{50, apparent} values of 3 µM and 0.04 µM, respectively. CYP2C9 IC_{50, apparent} values generated in human hepatocytes were systematically higher than those determined with rCYP2C9. After correcting for nonspecific binding, there was an excellent correlation of IC_{50, unbound} values generated in the different milieu (r² = 0.88, p < 0.0001). The ratio of inhibitor concentration at the entrance to the liver to the inhibition constant ([I]_in/K_i) was used to simulate clinical AUC changes and compared with that observed in vivo. Where [I]_{in, total}/K_{i, apparent} was used, there were zero false negatives (observed AUC 2, predicted AUC <2), eight correct assignations, and seven false positives (observed AUC 2, predicted AUC >2. Where [I]_{in, unbound}/K_{i, unbound} was used, there was one false negative, 14 correct assignations, and zero false positives. In summary, the data presented here suggest that for CYP2C9 interactions, the use of total liver inhibitor concentrations may indeed avoid false negatives, but more realistic predictions may be achieved using unbound liver inhibitor concentrations and unbound in vitro inhibition parameters.

This article has been cited by other articles:

				D. F. McGinnity, N. J. Waters, J. Tucker, and R. J. Riley Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions Drug Metab. Dispos., June 1, 2008; 36(6): 1126 - 1134. [Abstract] [Full Text] [PDF]

				V. Kumar, C. W. Locuson, Y. Y. Sham, and T. S. Tracy Amiodarone Analog-Dependent Effects on CYP2C9-Mediated Metabolism and Kinetic Profiles Drug Metab. Dispos., October 1, 2006; 34(10): 1688 - 1696. [Abstract] [Full Text] [PDF]

				D. F. McGinnity, A. J. Berry, J. R. Kenny, K. Grime, and R. J. Riley EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES Drug Metab. Dispos., August 1, 2006; 34(8): 1291 - 1300. [Abstract] [Full Text] [PDF]